Cover Image
市場調查報告書

Icon Bioscience, Inc. :產品平台分析

Icon Bioscience, Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 256083
出版日期 內容資訊 英文 28 Pages
訂單完成後即時交付
價格
Back to Top
Icon Bioscience, Inc. :產品平台分析 Icon Bioscience, Inc. - Product Pipeline Review - 2015
出版日期: 2015年08月31日 內容資訊: 英文 28 Pages
簡介

Icon Bioscience, Inc.是開發、銷售眼科用藥劑的生物製藥企業。該公司基於獨家的優良藥劑遞送系統開發產品,適用於青光眼,滲出型老齡化黃斑部病變,糖尿病黃斑部水腫,葡萄膜炎,角膜移植排斥反應等各種眼科疾病的治療。

本報告提供Icon Bioscience, Inc. 的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Icon Bioscience, Inc. 的基本資料

  • Icon Bioscience, Inc.概要
  • 主要資訊
  • 企業資料

Icon Bioscience, Inc. :R&D概要

  • 主要的治療範圍

Icon Bioscience, Inc. :開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

Icon Bioscience, Inc. :開發中產品概況

  • 最後階段的開發中產品
    • 第三階段的產品/聯合治療模式
  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

Icon Bioscience, Inc. :藥物簡介

  • dexamethasone acetate
  • triamcinolone acetonide
  • IBI-30090
  • IBI-70090
  • latanoprost
  • melphalan
  • Drug for Cornea Transplant Rejection
  • Drug for Diabetic Macular Edema
  • Drug for Proliferative Diabetic Retinopathy
  • Drug for Wet Age Related Macular Degeneration

Icon Bioscience, Inc. :開發平台分析

  • 標的別
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

Icon Bioscience, Inc. :最近的開發平台趨勢

Icon Bioscience, Inc. :總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC07363CDB

Summary

Global Markets Direct's, 'Icon Bioscience, Inc. - Product Pipeline Review - 2015', provides an overview of the Icon Bioscience, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Icon Bioscience, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Icon Bioscience, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Icon Bioscience, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Icon Bioscience, Inc.'s pipeline products

Reasons to buy

  • Evaluate Icon Bioscience, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Icon Bioscience, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Icon Bioscience, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Icon Bioscience, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Icon Bioscience, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Icon Bioscience, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Icon Bioscience, Inc. Snapshot
    • Icon Bioscience, Inc. Overview
    • Key Information
    • Key Facts
  • Icon Bioscience, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Icon Bioscience, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Icon Bioscience, Inc. - Pipeline Products Glance
    • Icon Bioscience, Inc. - Late Stage Pipeline Products
      • Phase III Products/Combination Treatment Modalities
    • Icon Bioscience, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Icon Bioscience, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Icon Bioscience, Inc. - Drug Profiles
    • dexamethasone acetate
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • triamcinolone acetonide
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • cyclosporine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • latanoprost
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • melphalan
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • methotrexate
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Icon Bioscience, Inc. - Pipeline Analysis
    • Icon Bioscience, Inc. - Pipeline Products by Target
    • Icon Bioscience, Inc. - Pipeline Products by Route of Administration
    • Icon Bioscience, Inc. - Pipeline Products by Molecule Type
    • Icon Bioscience, Inc. - Pipeline Products by Mechanism of Action
  • Icon Bioscience, Inc. - Recent Pipeline Updates
  • Icon Bioscience, Inc. - Dormant Projects
  • Icon Bioscience, Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Icon Bioscience, Inc., Key Information
  • Icon Bioscience, Inc., Key Facts
  • Icon Bioscience, Inc. - Pipeline by Indication, 2015
  • Icon Bioscience, Inc. - Pipeline by Stage of Development, 2015
  • Icon Bioscience, Inc. - Monotherapy Products in Pipeline, 2015
  • Icon Bioscience, Inc. - Phase III, 2015
  • Icon Bioscience, Inc. - Phase II, 2015
  • Icon Bioscience, Inc. - Phase I, 2015
  • Icon Bioscience, Inc. - Preclinical, 2015
  • Icon Bioscience, Inc. - Pipeline by Target, 2015
  • Icon Bioscience, Inc. - Pipeline by Route of Administration, 2015
  • Icon Bioscience, Inc. - Pipeline by Molecule Type, 2015
  • Icon Bioscience, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Icon Bioscience, Inc. - Recent Pipeline Updates, 2015
  • Icon Bioscience, Inc. - Dormant Developmental Projects,2015

List of Figures

  • Icon Bioscience, Inc. - Pipeline by Top 10 Indication, 2015
  • Icon Bioscience, Inc. - Pipeline by Stage of Development, 2015
  • Icon Bioscience, Inc. - Monotherapy Products in Pipeline, 2015
  • Icon Bioscience, Inc. - Pipeline by Top 10 Target, 2015
  • Icon Bioscience, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Icon Bioscience, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Icon Bioscience, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top